Rohit Kumar, MD
Pulmonary Disease · Philadelphia, PANPI 1831272384
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 74.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,037 and has fallen 96.3% since, to $39 in 2025. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 18 payments — averaging $70.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$946
- AstraZeneca$158
- Boston Scientific$93
- Amgen$21
- GSK$18
- Boehringer Ingelheim$16
- plus $15 from 1 others
What the payments were for
- Travel & lodging$61448%
- Food & beverage$60748%
- Education$464%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $946 |
| AstraZeneca | 5 | $158 |
| Boston Scientific | 3 | $93 |
| Amgen | 1 | $21 |
| GSK | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,267 in reported general payments places this provider in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $87,801 |
| Incruse ElliptaUmeclidinium Bromide | 146 | $69,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 94 | $53,497 |
| Spiriva RespimatTiotropium Bromide | 77 | $41,050 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $21,354 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,839 |
| Spiriva HandihalerTiotropium Bromide | 14 | $10,610 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 69 | $8,876 |
| EliquisApixaban | 14 | $8,169 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,837 |
| Roflumilast | 40 | $5,646 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $3,544 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,384 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,644 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $18 | $234,336401 claims |
| Boehringer IngelheimSpiriva Respimat | $16 | $41,05077 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $158 | $16,67635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.